The Wayback Machine - https://web.archive.org/web/20160616105840/https://en.wikipedia.org/wiki/Bupranolol

Bupranolol

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Bupranolol
Bupranolol.svg
Systematic (IUPAC) name
(RS)-1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol
Clinical data
Drugs.com International Drug Names
Routes of
administration
Oral, topical (eye drops)
Pharmacokinetic data
Bioavailability < 10%
Protein binding 76%
Metabolism First pass elimination > 90%
Biological half-life 2-4 hours (plasma)
Excretion > 88% renal (as carboxybupranolol)
Identifiers
CAS Number 23284-25-5 N
ATC code C07AA19 (WHO)
PubChem CID 2475
IUPHAR/BPS 550
DrugBank DB08808 YesY
ChemSpider 2381 YesY
UNII 858YGI5PIT YesY
KEGG D07590 N
ChEMBL CHEMBL305380 YesY
Chemical data
Formula C14H22ClNO2
Molar mass 271.78298 g/mol
 NYesY (what is this?)  (verify)

Bupranolol is a non-selective beta blocker without intrinsic sympathomimetic activity (ISA), but with strong membrane stabilizing activity. Its potency is similar to propranolol.

Uses and dosage[edit]

Like other beta blockers, oral bupranolol can be used to treat hypertension and tachycardia. The initial dose is 50 mg two times a day. It can be increased to 100 mg four times a day. Bupranolol eye drops (0.05%-0.5%) are used against glaucoma.

Pharmacology[edit]

Bupranolol is quickly and completely absorbed from the gut. Over 90% undergo first-pass metabolism. Bupranolol has a plasma half life of about two to four hours, with levels never reaching 1 µg/l in therapeutic doses. The main metabolite is carboxybupranolol, 4-chloro-3-[3-(1,1-dimethylethylamino)-2-hydroxy-propyloxy]benzoic acid – that is, the methyl group at the benzene ring is oxidized to a carboxyl group –, of which 88% are eliminated renally within 24 hours.

Adverse effects, contraindications, interactions[edit]

Adverse effects, contraindications and interactions are similar to other beta blockers.

References[edit]

  • Dinnendahl, V; Fricke, U, eds. (2007). Arzneistoff-Profile (in German) 2 (21 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3. 

Navigation menu

Personal tools

Namespaces

Variants

More

Morty Proxy This is a proxified and sanitized view of the page, visit original site.